Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Organogenesis Holdings (ORGO) over the last 10 years, with Q3 2025 value amounting to $509.8 million.

  • Organogenesis Holdings' Liabilities and Shareholders Equity rose 1423.52% to $509.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 709.47%. This contributed to the annual value of $497.9 million for FY2024, which is 823.02% up from last year.
  • Per Organogenesis Holdings' latest filing, its Liabilities and Shareholders Equity stood at $509.8 million for Q3 2025, which was up 1423.52% from $461.1 million recorded in Q2 2025.
  • Over the past 5 years, Organogenesis Holdings' Liabilities and Shareholders Equity peaked at $509.8 million during Q3 2025, and registered a low of $319.2 million during Q1 2021.
  • For the 5-year period, Organogenesis Holdings' Liabilities and Shareholders Equity averaged around $441.6 million, with its median value being $450.3 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 6424.27% in 2021, then plummeted by 353.42% in 2024.
  • Over the past 5 years, Organogenesis Holdings' Liabilities and Shareholders Equity (Quarter) stood at $443.3 million in 2021, then increased by 1.38% to $449.4 million in 2022, then rose by 2.37% to $460.0 million in 2023, then rose by 8.23% to $497.9 million in 2024, then grew by 2.4% to $509.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $509.8 million in Q3 2025, compared to $461.1 million in Q2 2025 and $467.4 million in Q1 2025.